The global pterygium drug market is projected to register a substantial CAGR of 6.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Global Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Region (North America, Europe, Asia-Pacific, South America, Middle East, and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global pterygium drug market are:
Increase in healthcare awareness to reduce the risk of eye illnesses
Rising geriatric population
Market Players:
Some of the major players operating in the global pterygium drug market are:
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Spectra Vision Care,
Thea Laboratories
Wellona Pharma
SAGER PHARMA
Maya Biotech Private Limited
EYERIS VISIONCARE Pvt. Ltd.
Sylentis
Bayer AG
Zydus Group
Amneal Pharmaceuticals LLC
OASIS Medical
Similasan Corporation
Alcon
Santen Pharmaceutical Co.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 OVERVIEW OF GLOBAL PTERYGIUM DRUG MARKET
- 1.4 CURRENCY AND PRICING
- 1.5 LIMITATIONS
- 1.6 MARKETS COVERED
2 GLOBAL PTERYGIUM DRUG MARKET: SEGMENTATION
- 2.1 MARKETS COVERED
- 2.2 GEOGRAPHICAL SCOPE
- 2.3 YEARS CONSIDERED FOR THE STUDY
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.6 MULTIVARIATE MODELLING
- 2.7 CLASS SEGMENT LIFELINE CURVE
- 2.8 DBMR MARKET POSITION GRID
- 2.9 VENDOR SHARE ANALYSIS
- 2.10 MARKET END USER COVERAGE GRID
- 2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PESTEL'S MODEL
- 4.2 PORTER'S 5 FORCES
- 4.3 GLOBAL PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 GLOBAL PTERYGIUM DRUG MARKET: REGULATIONS
- 7.1 REGULATION IN THE U.S.
7.2 REGULATION IN EUROPE:
7.3 REGULATIONS IN CHINA:
7.4 REGULATIONS IN INDIA:
7.5 RELEVANT ACTS FOR THIS FRAMEWORK:
8 MARKET OVERVIEW
- 8.1 DRIVERS
- 8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS
- 8.1.2 RISE IN GERIATRIC POPULATION
- 8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES
- 8.2 RESTRAINTS
- 8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION
- 8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS
- 8.3 OPPORTUNITIES
- 8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
- 8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
- 8.4 CHALLENGES
- 8.4.1 STRINGENT RULES & REGULATIONS
- 8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS
9 GLOBAL PTERYGIUM DRUG MARKET, BY DISEASE TYPE
- 9.1 OVERVIEW
- 9.2 PROGRESSIVE PTERYGIUM
- 9.3 ATROPHIC PTERYGIUM
10 GLOBAL PTERYGIUM DRUG MARKET, BY STAGES
- 10.1 OVERVIEW
- 10.2 STAGE 2
- 10.3 STAGE 3
- 10.4 STAGE 1
- 10.5 STAGE 4
11 GLOBAL PTERYGIUM DRUG MARKET, BY TREATMENT
- 11.1 OVERVIEW
- 11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
- 11.2.1 DEMULCENT
- 11.2.2 EMOLLIENTS
- 11.3 STEROID EYE DROPS
- 11.3.1 KETONE STEROIDS
- 11.3.1.1 PREDNOSOLONE
- 11.3.1.2 DEXAMETHASONE
- 11.3.1.3 FLUROMETHOLONE
- 11.3.1.4 OTHERS
- 11.3.2 ESTER STEROID (LOTERPREDNOL)
12 GLOBAL PTERYGIUM DRUG MARKET, BY FORMULATION
- 12.1 OVERVIEW
- 12.2 EYE DROPS
- 12.2.1 EYE DROPS WITH PRESERVATIVES
- 12.2.2 PRESERVATIVE-FREE EYE DROPS
- 12.3 EYE OINTMENTS
- 12.4 OTHERS
13 GLOBAL PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE
- 13.1 OVERVIEW
- 13.2 PRESCRIPTION
- 13.3 OVER THE COUNTER (OTC)
14 GLOBAL PTERYGIUM DRUG MARKET, BY POPULATION TYPE
- 14.1 OVERVIEW
- 14.2 GERIATRIC
- 14.3 ADULTS
15 GLOBAL PTERYGIUM DRUG MARKET, BY END USER
- 15.1 OVERVIEW
- 15.2 HOSPITALS
- 15.3 SPECIALTY CLINICS
- 15.4 HOME HEALTHCARE
- 15.5 OTHERS
16 GLOBAL PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL
- 16.1 OVERVIEW
- 16.2 RETAIL PHARMACIES
- 16.3 HOSPITAL PHARMACIES
- 16.4 ONLINE PHARMACIES
- 16.5 OTHERS
17 GLOBAL PTERYGIUM DRUG MARKET, BY REGION
- 17.1 OVERVIEW
- 17.2 ASIA-PACIFIC
- 17.2.1 CHINA
- 17.2.2 INDIA
- 17.2.3 JAPAN
- 17.2.4 INDONESIA
- 17.2.5 VIETNAM
- 17.2.6 THAILAND
- 17.2.7 PHILIPPINES
- 17.2.8 SOUTH KOREA
- 17.2.9 AUSTRALIA
- 17.2.10 MALAYSIA
- 17.2.11 SINGAPORE
- 17.2.12 REST OF ASIA-PACIFIC
- 17.3 NORTH AMERICA
- 17.3.1 U.S.
- 17.3.2 MEXICO
- 17.3.3 CANADA
- 17.4 EUROPE
- 17.4.1 RUSSIA
- 17.4.2 SPAIN
- 17.4.3 TURKEY
- 17.4.4 GERMANY
- 17.4.5 ITALY
- 17.4.6 U.K.
- 17.4.7 FRANCE
- 17.4.8 HUNGARY
- 17.4.9 AUSTRIA
- 17.4.10 SWITZERLAND
- 17.4.11 NETHERLANDS
- 17.4.12 POLAND
- 17.4.13 IRELAND
- 17.4.14 NORWAY
- 17.4.15 LITHUANIA
- 17.4.16 REST OF EUROPE
- 17.5 SOUTH AMERICA
- 17.5.1 BRAZIL
- 17.5.2 ARGENTINA
- 17.5.3 PERU
- 17.5.4 REST OF SOUTH AMERICA
- 17.6 MIDDLE EAST AND AFRICA
- 17.6.1 SOUTH AFRICA
- 17.6.2 EGYPT
- 17.6.3 ISRAEL
- 17.6.4 UAE
- 17.6.5 SAUDI ARABIA
- 17.6.6 KUWAIT
- 17.6.7 REST OF MIDDLE EAST AND AFRICA
18 GLOBAL PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE
- 18.1 COMPANY SHARE ANALYSIS: GLOBAL
- 18.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
- 18.3 COMPANY SHARE ANALYSIS: NORTH AMERICA
- 18.4 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILES
- 20.1 ALCON
- 20.1.1 COMPANY SNAPSHOT
- 20.1.2 RECENT FINANCIALS
- 20.1.3 COMPANY SHARE ANALYSIS
- 20.1.4 PRODUCT PORTFOLIO
- 20.1.5 RECENT DEVELOPMENTS
- 20.2 ABBVIE INC.
- 20.2.1 COMPANY SNAPSHOT
- 20.2.2 REVENUE ANALYSIS
- 20.2.3 COMPANY SHARE ANALYSIS
- 20.2.4 PRODUCT PORTFOLIO
- 20.2.5 RECENT DEVELOPMENT
- 20.3 BAUSCH & LOMB INCORPORATED
- 20.3.1 COMPANY SNAPSHOT
- 20.3.2 REVENUE ANALYSIS
- 20.3.3 COMPANY SHARE ANALYSIS
- 20.3.4 PRODUCT PORTFOLIO
- 20.3.5 RECENT DEVELOPMENT
- 20.4 JOHNSON & JOHNSON SERVICES, INC.
- 20.4.1 COMPANY SNAPSHOT
- 20.4.2 REVENUE ANALYSIS
- 20.4.3 COMPANY SHARE ANALYSIS
- 20.4.4 PRODUCT PORTFOLIO
- 20.4.5 RECENT DEVELOPMENTS
- 20.5 BAYER AG
- 20.5.1 COMPANY SNAPSHOT
- 20.5.2 REVENUE ANALYSIS
- 20.5.3 COMPANY SHARE ANALYSIS
- 20.5.4 PRODUCT PORTFOLIO
- 20.5.5 RECENT DEVELOPMENTS
- 20.6 NOVARTIS AG
- 20.6.1 COMPANY SNAPSHOT
- 20.6.2 REVENUE ANALYSIS
- 20.6.3 PRODUCT PORTFOLIO
- 20.6.4 RECENT DEVELOPMENTS
- 20.7 SANTEN PHARMACEUTICAL CO., LTD.
- 20.7.1 COMPANY SNAPSHOT
- 20.7.2 RECENT FINANCIALS
- 20.7.3 PRODUCT PORTFOLIO
- 20.7.4 RECENT DEVELOPMENT
- 20.8 AKORN OPERATING COMPANY LLC
- 20.8.1 COMPANY SNAPSHOT
- 20.8.2 PRODUCT PORTFOLIO
- 20.8.3 RECENT DEVELOPMENT
- 20.9 AMNEAL PHARMACEUTICALS LLC.
- 20.9.1 COMPANY SNAPSHOT
- 20.9.2 REVENUE ANALYSIS
- 20.9.3 PRODUCT PORTFOLIO
- 20.9.4 RECENT DEVELOPMENTS
- 20.10 EYERIS VISIONCARE PVT. LTD.
- 20.10.1 COMPANY SNAPSHOT
- 20.10.2 PRODUCT PORTFOLIO
- 20.10.3 RECENT DEVELOPMENTS
- 20.11 MAYA BIOTECH PRIVATE LIMITED
- 20.11.1 COMPANY SNAPSHOT
- 20.11.2 PRODUCT PORTFOLIO
- 20.11.3 RECENT DEVELOPMENTS
- 20.12 OASIS MEDICAL
- 20.12.1 COMPANY SNAPSHOT
- 20.12.2 PRODUCT PORTFOLIO
- 20.12.3 RECENT DEVELOPMENTS
- 20.13 PRESTIGE CONSUMER HEALTHCARE INC.
- 20.13.1 COMPANY SNAPSHOT
- 20.13.2 REVENUE ANALYSIS
- 20.13.3 PRODUCT PORTFOLIO
- 20.13.4 RECENT DEVELOPMENT
- 20.14 SAGER PHARMA
- 20.14.1 COMPANY SNAPSHOT
- 20.14.2 PRODUCT PORTFOLIO
- 20.14.3 RECENT DEVELOPMENTS
- 20.15 SIMILASAN CORPORATION
- 20.15.1 COMPANY SNAPSHOT
- 20.15.2 PRODUCT PORTFOLIO
- 20.15.3 RECENT DEVELOPMENTS
- 20.16 SPECTRA VISION CARE
- 20.16.1 COMPANY SNAPSHOT
- 20.16.2 PRODUCT PORTFOLIO
- 20.16.3 RECENT DEVELOPMENTS
- 20.17 SYLENTIS
- 20.17.1 COMPANY SNAPSHOT
- 20.17.2 PRODUCT PORTFOLIO
- 20.17.3 RECENT DEVELOPMENT
- 20.18 THEA LABORATORIES
- 20.18.1 COMPANY SNAPSHOT
- 20.18.2 PRODUCT PORTFOLIO
- 20.18.3 RECENT DEVELOPMENTS
- 20.19 WELLONA PHARMA
- 20.19.1 COMPANY SNAPSHOT
- 20.19.2 PRODUCT PORTFOLIO
- 20.19.3 RECENT DEVELOPMENTS
- 20.20 ZYDUS GROUP
- 20.20.1 COMPANY SNAPSHOT
- 20.20.2 REVENUE ANALYSIS
- 20.20.3 PRODUCT PORTFOLIO
- 20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS